Managing Metastatic NSCLC: Strategies for Treatment Selection
This activity contains:
- CME/CPE/CNE-Certified Live Grand Rounds and Webinars
- Downloadable Slide Deck (a non-certified educational resource)
- Pocket Reference Guide (a non-certified educational resource)
The goal of this activity is to educate clinicians about recent developments in the treatment of metastatic non–small cell lung cancer (NSCLC) and to provide them with the information necessary to make best use of the available therapies.
The treatment of NSCLC has changed significantly as a result of the identification of clinically relevant biomarkers and the development of targeted therapies. Although patient outcomes have improved as a result of treatment advances, metastatic disease is still an important challenge. Knowledge and practice gaps can be seen in several aspects of the treatment of metastatic NSCLC, such as how to integrate new therapies into practice, manage toxicities associated with new therapies, and make best use of a shared decision-making approach to treatment.
This Grand Rounds initiative is designed to close these knowledge gaps and provide clinicians with up-to-date information about therapies for NSCLC so that they can make informed choices regarding management and patient education. Topics covered in this activity include the indications, efficacy, and safety of recently approved therapies; how to integrate these therapies into practice; and how to apply a shared decision-making approach when working with patients who have metastatic NSCLC.
This activity is intended for community oncologists, nurses, pharmacists, and other healthcare professionals who manage NSCLC.
At the conclusion of this activity, participants should be better able to:
- Summarize the indications, efficacy, and safety profiles of recently approved therapies for NSCLC
- Devise treatment selection and drug sequencing strategies that incorporate newer therapies for patients with metastatic NSCLC
- Implement management plans for the potential toxicities associated with therapies used for NSCLC
- Summarize the key components of patient education and shared decision making in the treatment of NSCLC
- Activity Overview
- The Foundation of Targeted Therapies for NSCLC
- Treatment Strategies for Metastatic NSCLC
- Case-Based Discussion of Treatment Selection and Shared Decision Making
David S. Ettinger, MD, FACP, FCCP
Jeffrey Crawford, MD
Barbara J. Gitlitz, MD
Fred R. Hirsch, MD, PhD
Leora Horn, MD, MSc, FRCPC
Benjamin Levy, MD
Roman Perez-Soler, MD
David Spigel, MD
Continuing Medical Education
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit. UAN 0592-0000-16-016-L01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|David S. Ettinger, MD, FACP, FCCP||Research grant: Golden Biotech Corp; Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Ariad Pharmaceuticals, Inc; Boehringer Ingelheim; Bristol-Myers Squibb Co; Eli Lilly and Co; EMD Serono, Inc; Genentech, Inc; Helsinn Therapeutics (US) Inc.|
|Jeffrey Crawford, MD||Data and safety monitoring board member: Celgene Corp; G1 Therapeutics; Janssen Pharmaceuticals, Inc; Merrimack Pharmaceuticals; Roche; Institutional principal investigator: Amgen, Inc; AstraZeneca Pharmaceuticals LP; Bayer Pharmaceuticals Corp; Clovis Oncology; GTx; MedImmune; Scientific advisor: Merck & Co, Inc; Novartis Pharmaceuticals Corp; Pfizer, Inc.|
|Barbara J. Gitlitz, MD||Advisor: Ariad Pharmaceuticals, Inc; Celgene Corp; Clovis Oncology; Serve(d) as a speaker or a member of a speakers bureau for: Eli Lilly and Co; Genentech, Inc.|
|Fred R. Hirsch, MD, PhD||Consultant/Advisory boards: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Co; Eli Lilly and Co; Genentech, Inc; Merck & Co., Inc; Ventana; Research grant through University of Colorado Lab: Amgen, Inc; Bayer Pharmaceuticals Corp; Eli Lilly and Co; Genentech, Inc.|
|Leora Horn, MD, MSc, FRCPC||Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Bayer Pharmaceuticals Corp; Boehringer Ingelheim; Bristol-Myers Squibb Co; Eli Lilly and Co; Genentech, Inc; Merck & Co, Inc; Xcovery; Serve(d) as a speaker or a member of a speakers bureau for: Biodesix, Inc.|
|Benjamin Levy, MD||Received income in any amount from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Celgene Corp; Eli Lilly and Co; Genentech, Inc; Merck & Co, Inc; Pfizer, Inc; Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Celgene Corp; Eli Lilly and Co; Genentech, Inc; Merck & Co, Inc; Pfizer, Inc; Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc.|
|Roman Perez-Soler, MD||No real or apparent conflicts of interest to report.|
|David Spigel, MD||No real or apparent conflicts of interest to report.|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda-Gracie-King, MS, Ronald Viggiani, MD, Isabelle Vacher, Sarah Williams, PhD, Jocelyn Timko, and Marilyn Haas, PhD, RN, CNS, ANP-BC state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
There is no fee for this educational activity.
This activity is provided by
- 1.00 ACPE
- 1.00 ANCC
- 1.00 AMA PRA Category 1 Credit™